Determinants of Coronary Calcium Conversion Among Patients With a Normal Coronary Calcium Scan What Is the “Warranty Period” for Remaining Normal? by Min, James K. et al.
C
a
a
(
c
u
m
F
U
S
M
a
M
a
H
a
Journal of the American College of Cardiology Vol. 55, No. 11, 2010
© 2010 by the American College of Cardiology Foundation ISSN 0735-1097/10/$36.00
PCardiac Imaging
Determinants of Coronary
Calcium Conversion Among Patients
With a Normal Coronary Calcium Scan
What Is the “Warranty Period” for Remaining Normal?
James K. Min, MD,* Fay Y. Lin, MD,* David S. Gidseg, MD,* Jonathan W. Weinsaft, MD,*
Daniel S. Berman, MD,† Leslee J. Shaw, PHD,‡ Alan Rozanski, MD,§ Tracy Q. Callister, MD
New York, New York; Los Angeles, California; Atlanta, Georgia; and Hendersonville, Tennessee
Objectives This study identified the incidence and predictors of conversion of a normal to abnormal coronary artery calcium
(CAC) scan during serial CAC scanning over 5 years.
Background Although a normal CAC scan signifies absence of significant atherosclerosis and is used to identify individuals at
low clinical risk, the “warranty period” of a normal CAC scan relative to its ability to predict sustained absence of
coronary atherosclerosis remains unknown.
Methods We assessed frequency of and time to progression, as well as proportional increase of CAC in 422 individuals
with normal CAC scan (CAC  0) undergoing annual CAC scanning for 5 years. Results were compared with
those of a referent cohort of 621 individuals with baseline CAC scan (CAC 0).
Results A total of 106 (25.1%) patients with CAC  0 developed CAC during follow-up at a mean time to conversion of
4.1  0.9 years. Incidence of conversion to CAC 0 was nonlinear and was highest in the fifth year. In multivari-
able analysis, progression to CAC 0 was associated with age, diabetes, and smoking (p  0.01 for all). Among
the 621 individuals with baseline CAC 0, only the presence of CAC itself, rather than CAD risk factors, was pre-
dictive of CAC progression. Among propensity score-matched individuals with CAC 0 versus CAC  0, baseline
CAC 0 emerged as the strongest predictor of CAC progression (hazard ratio [HR]: 12.50, 95% confidence inter-
val [CI]: 9.31 to 16.77), followed by diabetes (HR: 2.07, 95% CI: 1.47 to 2.90) and smoking (HR: 1.29, 95% CI:
1.02 to 1.63, p  0.05 for all).
Conclusions Among individuals with CAC  0, conversion to CAC 0 is nonlinear and occurs at low frequency before 4 years.
No clinical factor seems to mandate earlier repeat CAC scanning. (J Am Coll Cardiol 2010;55:1110–7) © 2010
by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.08.088s
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woronary artery calcium (CAC) scoring has been proposed
s a useful atherosclerosis imaging method for stratification
nd reclassification of risk of coronary heart disease (CHD)
1,2). Coronary atherosclerotic lesions often contain cal-
ified components, which can be precisely measured
sing either electron beam computed tomography or
ultidetector computed tomography by the Agatston
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niversity, The New York Presbyterian Hospital, New York, New York; †Cedars-
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edicine, Atlanta, Georgia; §St. Luke’s Roosevelt Hospital, New York, New York;
nd the Tennessee Heart and Vascular Institute, Hendersonville, Tennessee. Dr.
in has received research support from and is on the Speakers’ Bureau and medical
dvisory board of GE Healthcare. Dr. Berman has received grant support from GE
ealthcare and Siemens. Dr. Callister is on the Speakers’ Bureau of GE Healthcare.n
Manuscript received June 15, 2009; revised manuscript received August 17, 2009,
ccepted August 24, 2009.coring method (3). Increasing degrees of CAC predict
dverse CHD events and all-cause mortality (4 –17),
hereas a normal CAC scan is a reliable predictor for low
isk and is used clinically to signify the absence of any
ajor atherosclerosis. Relatively little study has been
erformed, however, to examine the temporal conversion
f CAC and the clinical factors that influence CAC
rogression. Three recent cohort studies have addressed
he issue of CHD risk factors and CAC progression, and
n each study, a constant conversion and progression rate
or CAC has been assumed (18 –20).
See page 1118
To address this issue prospectively, in the present study
e uniquely followed up a cohort of patients who had
ormal CAC scans at baseline with yearly CAC scans for 5
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March 16, 2010:1110–7 Warranty Period of a Zero CAC Scoreears. Our goals were both to test the assumption of a linear
onversion rate for CAC and to evaluate the factors that
ight predict a more accelerated rate of conversion from a
ormal to an abnormal CAC scan. Comparisons were made
o a contrasting group of patients with an abnormal CAC
can for this purpose.
ethods
tudy population. Our study population was recruited from
atients who were referred for CAC scanning at the Tennessee
eart and Vascular Institute on a clinical basis by their primary
are physicians. From these, we identified 422 patients who
ad a 0 CAC score (the CAC  0 group) who agreed to
ndergo yearly serial CAC scanning or until the detection of a
ositive CAC score, whichever came first. As a contrasting
roup, we also identified 621 individuals who underwent at
east 2 CAC tests at the same time, of which the first CAC
core was more than 0. Patients with known coronary artery
isease (CAD) were excluded from this study, as defined by a
istory of prior myocardial infarction or coronary revascular-
zation procedure or a prior abnormal stress test.
Before the initiation of the CAC score, a nurse or research
oordinator prospectively collected information with regard to
he presence of categorical cardiac conditions for each individ-
al by written questionnaire. Systemic arterial hypertension
as defined by a blood pressure 140/90 mm Hg, a docu-
ented prior history of high blood pressure, or treatment with
ntihypertensive medications. Diabetes mellitus was defined as
fasting glucose of 126 mg/dl, a prior established diagnosis of
iabetes by a physician, and/or treatment with insulin or oral
ypoglycemic agents. Dyslipidemia was defined as a fasting
otal cholesterol200 mg/dl. In the present study, all individ-
als with dyslipidemia were actively treated with cholesterol-
owering medications. Smoking history was obtained by self-
eport by query of both past and active smoking use. A history
f CAD was defined as prior myocardial infarction, prior
oronary revascularization by percutaneous intervention, or
oronary artery bypass surgery or prior abnormal stress test. A
odified Framingham risk score was then calculated for all
atients as previously described. This study was approved by
he Medical Ethics Committee of Tennessee Heart and
ascular Institute.
AC scoring. The CAC scoring was performed using elec-
ron beam computed tomography (Imatron C-150, Imatron,
an Francisco, California). Approximately 30 to 40 contig-
ous axial slices of 3-mm thickness were acquired. Coronary
rtery calcification was defined as a minimum of 3 contig-
ous pixels with a peak Hounsfield unit density 130.
oronary artery calcifications were scored by a certified
omputed tomography technologist, and were subsequently
lindly over-read by a board-certified cardiologist (T.Q.C.)
ith experience having interpreted more than 10,000 CAC
xaminations.
Among the CAC 0 group, conversion was defined by theevelopment of any CAC (i.e., CAC 0) during any of the 0ubsequent serial scans performed
n this study population. Among
he patients in the CAC0 group,
ny increase in the CAC score from
aseline to the subsequent scan
as defined as progression.
tatistical analysis. For all sta-
istical analyses, SPSS version 12.0
SPSS Inc., Chicago, Illinois) was
sed. Categorical variables are pre-
ented as frequencies and percent-
ges and continuous variables as
ean 1 SD, and were compared
sing Pearson chi-squared tests.
ontinuous variables were compared by Student unpaired t
ests or nonparametric Wilcoxon rank sum tests. Among the
AC 0 patients, conversion to CAC0 was modeled using
aplan-Meier and life table analysis. Univariable and stepwise
orward multivariable Cox proportional hazards models were
sed to estimate the impact of risk factors on conversion to CAC
0. Repeated-measures analysis of variance was used to
stimate the impact of risk factors for the magnitude of
AC increase over the observation period. Among the
AC 0 group, univariable and multivariable Cox propor-
ional hazards regression was used to estimate the impact of
isk factors on progression to a higher CAC score. As there
ere only 2 CAC observations in the CAC 0 group, rates
f increase were calculated as the magnitude of calcium
ncrease divided by the time between observation and
ompared using the Student t test.
To compare the effect of demographics and risk factors on
AC conversion or progression in individuals with CAC  0
nd CAC 0, a propensity score was developed to estimate
he pre-test likelihood of coronary atherosclerosis based on
ge, sex, smoking status, diabetes mellitus, hypertension,
nd dyslipidemia. The balancing property was achieved with
ll risk factors for the propensity score. The c-statistic for
he score was 0.79. The CAC  0 and CAC 0 group
atients were stratified into 8 balanced blocks, then matched
:1 within the same block, with CAC  0 patients
iscarded if they lacked a match. Propensity-matched
roups were then compared using the Wilcoxon rank sum
ests for continuous variables and the McNemar test for
ategorical variables in univariable analysis for the binary
utcome of conversion to a higher score. Cox proportional
azards regression was performed, evaluating the overall
roup containing both the propensity-matched CAC  0
nd CAC 0 group individuals for the relative hazard of
onversion to a higher score both in univariable and step-
ise forward multivariable analysis.
esults
he clinical characteristics for both the CAC  0 group and
he CAC0 group are listed in Table 1. Within the CAC
Abbreviations
and Acronyms
CAC  coronary artery
calcium
CAD  coronary artery
disease
CHD  coronary heart
disease
CI  confidence interval
CKD  chronic kidney
disease
HR  hazard ratiogroup, approximately one-half had hypertension, nearly
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Warranty Period of a Zero CAC Score March 16, 2010:1110–7wo-thirds had dyslipidemia, and overall 92.2% of these
atients had 1 CAD risk factor. The mean number of
AD risk factors in this group was 2.1  1.1. Patients in
he CAC0 group were older, were more likely to be male,
nd had higher rates of hypertension, diabetes, and dyslip-
demia than the patients with a score of CAC  0. The
ean number of CAD risk factors in the CAC 0 group
as 2.4  1.1 (p  0.001 vs. CAC  0 patients).
ccordingly, the CAC0 group had a higher Framingham
stimated 10-year risk score.
requency and extent of progression of CAC  0 to
AC >0. Overall, 106 (25.1%) individuals with no base-
ine CAC converted to a positive CAC score during the
ollow-up period. Conversion from a CAC  0 to a CAC
0 score occurred in 2 (0.5%), 5 (1.2%), 24 (5.7%), 26
6.2%), and 49 (11.6%) individuals at follow-up years 1, 2,
, 4, and 5, respectively (Fig. 1). Among the 106 patients
ho converted from CAC  0 to CAC 0, age, smoking,
iabetes, hypertension, and smoking status at baseline were
ignificantly associated with the risk of conversion to a
ositive CAC score over 5 years of observation (Table 2).
he average time to conversion from a normal to abnormal
Figure 1 Conversion of Individuals With a Baseline
Score of CAC  0 to CAC >0 Over Time
Both cumulative percent (red line) as well as yearly incidence (blue line)
of coronary artery calcium (CAC) conversion is low before the first 4 years.
Demographics of Patients With a Baseline Scorof CAC  0 and CAC >0 and the Matched CohoTable 1 Demographics of Patients With a Bof CAC  0 and CAC >0 and the M
CAC  0 (n  422)
Age (yrs) 48.8 (8.9)
Female 220 (52.1%)
Hypertension 194 (46.0%)
Diabetes 40 (9.5%)
Smoker 135 (32.0%)
Dyslipidemia 280 (66.4%)
Framingham risk score 9.3% (6.8%)
Risk factors 2.1 (1.1)
Values are mean (SD) or n (%).
CAC  coronary artery calcium.CAC scan in this cohort was 4.1  0.9 years, but no
raditional cardiovascular risk factors, including even age,
ere associated with accelerated times to conversion from
AC  0 to CAC 0. In multivariate Cox proportional
azards regression, only diabetes, age 40 years, and
moking independently increased the hazard of conversion
o CAC 0 (Table 3). Among those who converted, the
verage CAC score at the time of conversion was 19  19.
omparison with individuals with an initial score of
AC >0. Overall, 497 (80.0%) of 621 individuals with
baseline positive CAC score experienced progression of
AC during a mean of 1.9  1.1 years of follow-up.
he average rate of increase in the CAC 0 group was
5.5  89.6. The risk of progression over the observation
eriod was predicted by male sex, hyperlipidemia, smok-
ng status, and baseline CAC score (Table 4). In univar-
ate Cox proportional hazards regression, smoking and
aseline CAC scores were associated with increased
azards of CAC progression, whereas in multivariate
nalysis only baseline CAC score was independently
ssociated with increased hazard of progression (hazard
atio [HR]: 1.49, 95% confidence interval [CI]: 1.21 to
.84) (Table 5).
Rates of CAC increase were incrementally higher for
ndividuals with higher baseline CAC scores. Individuals
ith higher baseline CAC scores at the 100, 400, 600, and
,000 Agatston score threshold experienced particularly
igher rates of CAC increase compared with individuals
ith lower baseline CAC score (Fig. 2).
omparison of conversion to higher CAC score among
ropensity-matched individuals with CAC  0 versus
AC >0. Both propensity-matched groups included 266
atients. The propensity-matched group was intermediate
n risk factor prevalence (mean number of risk factors 2.3)
nd Framingham risk score between the CAC  0 and
AC 0 groups (Table 1). There were no significant
ifferences between matched CAC  0 and CAC 0
roups for age, sex, hyperlipidemia, hypertension, smoking,
r diabetes (p  0.2 for all, not shown). Even among
atched patients, there were higher frequencies of conver-
ion or progression for individuals with a baseline score of
e Score
ed Cohort
0 (n  621) p Value Matched (n  532)
6.6 (8.6) 0.001 52.2 (8.5)
33 (37.5%) 0.001 265 (49.8%)
51 (56.5%) 0.001 286 (53.8%)
01 (16.3%) 0.002 54 (10.2%)
26 (36.4%) 0.142 187 (35.2%)
76 (76.7%) 0.001 397 (74.6%)
9% (10.6%) 0.001 11.9% (8.1%)
2.4 (1.1) 0.001 2.3 (2.3)ertaselin
atch
CAC >
5
2
3
1
2
4
15.AC 0. In multivariate Cox regression, CAC 0 (HR:
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March 16, 2010:1110–7 Warranty Period of a Zero CAC Score4.96, 95% CI: 11.22 to 19.96, p 0.001) was the strongest
ndependent predictor of CAC conversion or progression,
ollowed by diabetes (HR: 2.07, 95% CI: 1.47 to 2.90, p 
.001) and smoking (HR: 1.29, 95% CI: 1.02 to 1.63, p 
.029) respectively (Table 6).
iscussion
ur study provides unique insights into the “warranty
eriod” relative to a CAC scan remaining normal over time.
e observed that there was a substantial 4-year lag period
efore coronary calcium development in asymptomatic in-
ividuals with baseline CHD risk factors but a score of
AC  0. Moreover, the rates of CAC conversion in this
ohort of individuals were nonlinear: extremely low in the
rst 2 years of serial scanning and accelerating substantially
n year 4 to 5. Thus, our present detailed examination of the
atural history of coronary calcium conversion indicates a
ow yield to repeat scanning in the initial years after an index
AC scan. In addition, the absence of conversion in the
Conversion Rates for Patients With a Baseline STable 2 Conversion Rates for Patients With
Risk Factor Converted
Female 52/220 (23.6%)
Male 54/202 (26.7%)
Hypertension 59/194 (30.4%)
No hypertension 47/228 (20.6%)
Diabetes mellitus 19/40 (47.5%)
No diabetes mellitus 87/382 (22.8%)
Smoker 49/135 (36.3%)
No smoker 57/287 (19.9%)
Dyslipidemia 76/280 (27.1%)
No dyslipidemia 30/142 (21.1%)
Age, yrs
65 7/22 (31.8%)
65 99/400 (24.8%)
50 54/105 (51.4%)
50 52/263 (19.8%)
40 101/369 (27.3%)
40 5/53 (9.4%)
CAC  coronary artery calcium.
Univariate and Multivariate Cox Proportional Hafor CAC Progression in Individuals With a BaselTable 3 Univariate a M ltivaria e Cox Profor CAC Progression in Individuals W
Risk Factor Univariate HR
Age (per yr) 1.02 (1–1.04)
Male 0.88 (0.6–1.29)
Dyslipidemia 1.29 (0.84–1.97)
Hypertension 1.47 (1–2.16)
Diabetes mellitus 2.42 (1.47–3.99)
Smoking 1.79 (1.22–2.64)
Age, yrs
65 1.28 (0.59–2.75)
50 1.49 (1.01–2.19)
40 2.77 (1.12–6.81)CAC  coronary artery calcium; HR  hazard ratio; N/A  not applicable.ntermediate term of 2 to 3 years provided no reassurance
egarding the future likelihood of conversion of a normal
AC scan because the incidence of conversion was 13.4% at
ear 4 and 25.1% at year 5.
With respect to clinical predictors of conversion of a
ormal CAC scan, we observed that certain traditional
HD risk factors, including age, diabetes, hypertension,
nd smoking status, were independently associated with
ncident conversion and absolute CAC score on conversion.
owever, there was no difference in time to conversion to
n abnormal scan among individuals showing any specific
raditional cardiovascular risk factor or among patients
tratified by age. Thus, it is unlikely that clinical factors may
rove to identify a subgroup for whom early repeat CAC
canning may be warranted among patients with a normal
can.
Limited prior studies have evaluated the rates of conver-
ion and progression of CAC in individuals with a baseline
core of CAC  0 by estimating annualized differences
of CAC  0seline Score of CAC  0
lue Time to Conversion, yrs p Value
6 4.00 1.05 0.118
4.29 0.80
21 4.03 0.96 0.171
4.29 0.89
01 4.33 0.84 0.350
4.10 0.96
01 4.12 0.88 0.825
4.16 1.00
4.01 1.00 0.113
4.38 0.73
57 4.29 0.95 0.682
4.13 0.94
01 4.19 0.94 0.625
4.10 0.94
05 4.15 0.94 0.72
4.00 1.00
Regressioncore of CAC  0onal Hazards Regression
Baseline Score of CAC  0
Value Multivariate HR p Value
.04 N/A N/A
.53 N/A N/A
.24 N/A N/A
.05 N/A N/A
.001 2.40 (1.45–3.95) 0.0005
.003 1.68 (1.14–2.48) 0.008
.53 N/A N/A
.04 N/A N/A
.03 2.87 (1.16–7.09) 0.02corea Ba
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Warranty Period of a Zero CAC Score March 16, 2010:1110–7etween 2 CAC scans (18–20). Recently, assessment of
,656 individuals with 2 CAC scans was performed in the
ESA (Multi-Ethnic Study of Atherosclerosis) cohort. In
n average follow-up of 2.4 years, traditional risk factors
ere associated with CAC incidence and progression in
ndividuals undergoing 2 scans. Similar findings were iden-
ified in a smaller study of 217 individuals undergoing 2
AC scans by electron beam computed tomography. In
oth of these studies, the nonparametric increase in CAC
as assumed to be logarithmic. However, as only 2 scans
ere performed on study participants in these 2 studies, the
ssumed constant rate of CAC progression may be incor-
ect, as indicated by the results of our study. Furthermore,
ates of CAC progression indicate an estimated annualized
ate of progression and do not wholly account for the
atients With Baseline PositiveAC Scores Showing a CAC IncreaseTable 4 Patients With Bas line PositiveCAC Scores Showing a CAC Increase
Increased Risk Factors
p ValueAbsent Present
Entire group 124 497 N/A
Male 325/388 172/233 0.003
Cholesterol 103/145 394/476 0.002
Hypertension 207/270 290/351 0.066
Diabetes mellitus 415/520 82/101 0.751
Smoker 298/395 199/226 0.001
Age, yrs
65 413/508 84/113 0.094
50 93/111 404/510 0.276
40 11/14 486/607 0.890
CAC
100 219/282 278/339 0.178
400 382/487 115/134 0.059
600 424/539 73/82 0.029
1,000 466/588 31/33 0.04
bbreviations as in Table 3.
Univariate and Multivariate Cox Proportional Hafor CAC Progression in Individuals With a BaselTable 5 Univariate a M ltivaria e Cox Profor CAC Progression in Individuals W
Univariate HR
Age (per yr) 1.00 (0.99–1.01)
Male 0.91 (0.75–1.09)
Cholesterol 0.81 (0.65–1.01)
Hypertension 1.03 (0.86–1.23)
Diabetes mellitus 1.05 (0.83–1.33)
Smoking 1.20 (1.00–1.44)
Age, yrs
65 1.06 (0.84–1.35)
50 0.96 (0.77–1.2)
40 0.95 (0.52–1.73)
CAC
100 1.22 (1.02–1.45)
400 1.49 (1.21–1.84)
600 1.81 (1.40–2.33)
1,000 1.64 (1.14–2.37)Abbreviations as in Table 3.ignificant lag period in which an individuals with a CAC
shows no progression of CAC, and thus no increased risk.
ur study differs from theirs in that we evaluated yearly
AC score by annual scanning, thereby permitting accurate
ssessment of the significant lag period before CAC in-
reases in addition to the relative contribution of age, sex,
nd CHD risk factors for CAC conversion.
It is noteworthy to mention that we used the Agatston
ethod of CAC scoring for this study. Although we have
escribed that other methods of CAC scoring exist, such as
he volumetric CAC score, which may reduce interscan
ariability, the majority of studies examining the outcomes
f individuals undergoing CAC scanning have used the
Figure 2
Median Magnitude of CAC Increase Over the Period
of Observation for Individuals With CAC Scores
Above or Below 100, 400, 600, and 1,000
The magnitude of increase in the coronary artery calcium (CAC) score is highly
dependent on the baseline CAC score. Blue bars  median change for initial
score below threshold; red bars  median change for initial score above
threshold. Wilcoxon rank sum p  0.001.
Ratiocore f CAC >0on l Hazards Ratio
Baseline Score of CAC >0
Value Multivariate HR p Value
383
326
064
741
666
039
575
762
874
029
001 1.49 (1.21–1.84) 0.001
0001
007zardsine Sporti
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March 16, 2010:1110–7 Warranty Period of a Zero CAC Scoregatston method, and we thus elected to use this in our
tudy as well (21). As individuals in our study were under-
oing sequential testing by CAC scanning, we elected not to
erform interscan reproducibility studies on this cohort.
evertheless, prior studies have evaluated the interscan
eproducibility of CAC scoring by the Agatston method on
he type of computed tomography scanner used for this
tudy, indicating that the variability is 20% (22). Al-
hough this variability is generally low, it is possible that
ariability among CAC tests in subsequent compared with
rior years may have affected the apparent progression of
AC. However, because CAC scanning is a test commonly
sed in clinical practice as a single examination rather than
ultiple examinations, performance of multiple CAC tests
t the same setting is impracticable and we elected not to
erform it.
Notably, a true baseline measurement is absent in this
ohort, and it remains uncertain whether earlier perfor-
ance of CAC scanning in individuals would result in a
imilar or more extended warranty period. Clinicians wish-
ng to extrapolate the present data to practice should keep
his in mind, but can use these data as a benchmark for
iddle-age, low- to intermediate-risk individuals.
omparison with patients with an initially abnormal
AC scan. Among patients with CAC at baseline exam-
nation, only smoking and cholesterol were significant
redictors of progression of CAC at 4 years. It is important
o note in this regard that the follow-up period to repeat
AC scanning in this group was significantly shorter than
mong the patients with normal CAC scans. Thus, it is
ossible that CAD risk factors may have emerged as a more
owerful predictor of CAC scan progression had the follow-up
eriod between scans been longer. Nevertheless, the presence
f CAC itself was a strong predictor of further CAC progres-
ion over time, as shown in prior studies. Once this factor was
ncluded in a multivariate analysis of CAC progression among
hose with an abnormal CAC scan at baseline, no CHD risk
actor was a predictor of CAC progression.
tudy limitations. The chief limitation to our study was a
ack of information regarding how patients with a normal
AC scan were treated by their primary physicians. The
reatment of CHD risk factors was left to the discretion of
he primary care physician and study participant, which
Univariate and Multivariate Cox Proportional HaComparison for CAC Progr ssion in Prope sity-MTable 6 Univariate and Multivariate Cox ProComparison for CAC Progression in
Univariate HR
Age (per yr) 1 (0.98–1.01)
Male 0.85 (0.67–1.07)
Cholesterol 1.08 (0.83–1.41)
Hypertension 1.28 (1.02–1.61)
Diabetes mellitus 1.63 (1.17–2.26)
Smoking 1.33 (1.05–1.67)
CAC 0 11.7 (8.75–15.64)
Abbreviations as in Table 3.ould result in significant treatment bias. Thus, it is difficult uo determine the magnitude of any confounding effect of
reatment for hypertension, diabetes, and dyslipidemia,
hich may have altered the natural course of CAC progres-
ion. Moreover, all individuals with dyslipidemia in the
resent analysis were being actively treated with statin
edications, potentially accounting for a lack of effect of
yslipidemia on CAC conversion and progression. Because
rior studies indicate a potential role for statin use and
etardation of CAC progression (23), caution should be
pplied to interpreting our results among patients who are
ot receiving lipid-lowering therapy. Nevertheless, the
resent results reflect real-world practice, in which patients
ay be treated based on their prevalent CHD risk factors,
nd indeed, acted on more aggressively according to baseline
AC score. To withhold treatment for the purposes of this
tudy would have been unfeasible.
Further, it remains possible that unmanifested subclinical
hronic kidney disease (CKD) may have contributed to the
resence, and perhaps progression, of CAC. Recent data
rom the Dallas Heart Study indicate the presence of CKD
s an additional potential mechanism for high CAC score,
hich may be related to novel markers of CAC presence,
ncluding the calcium–phosphorous product, homocysteine,
r osteoprotegerin (24,25). Certainly, in patients with severe
KD undergoing hemodialysis, other novel factors, such as
se of specific phosphate binders, are associated with CAC
rogression, although this is not the specific population
tudied here (26). Additional unmeasured confounders,
uch as the metabolic syndrome, other novel inflammatory
arkers, or additional factors that may modify calcification
rocesses (e.g., fetuin A), may mediate this accelerated risk
eyond traditional risk factors included in the Framingham
isk assessment. This study did not evaluate such markers,
ut instead limited its evaluation of CAC progression to
raditional CAD risk factors.
Of note, the unique design of our study called for small
ut non-negligible doses of radiation (27). In the current
tudy, the estimated effective biological radiation dose of
AC scans was 0.5 mSv. For individuals with baseline score
f CAC  0 who completed 5 annual CAC scans, the total
ose was in the range of 2.5 mSv. Although this value
epresents the annual background radiation derived from
mbient radon, the use of annual scanning for CAC seems
Ratioed C horton l Hazards Ratio
ensity-Matched Cohort
lue Multivariate HR p Value
34
7
45
31
04 2.07 (1.47–2.9) 0.001
15 1.29 (1.02–1.63) 0.029
28 14.96 (11.22–19.96) 0.001zardstchporti
Prop
p Va
0.8
0.1
0.5
0.0
0.0
0.0
0.8njustified based on our results. Rather, our study now
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indow for considering repeat CAC scanning among pa-
ients with normal CAC scans.
linical implications. These findings of the determinants
f CAC conversion and progression in individuals without
nd with baseline CAC scores have important implications.
ecently, some have advocated for atherosclerosis imaging,
ncluding CAC scanning, for assessment of asymptomatic
dult individuals of intermediate pre-test risk in accordance
o the American College of Cardiology Foundation/
merican Heart Association 2007 Clinical Expert Consen-
us Document, which indicates that the “evidence suggests
hat asymptomatic individuals with an intermediate FRS
Framingham risk score] may be reasonable candidates for
HD testing using CAC scanning as a potential means of
odifying risk prediction and altering therapy” (1,28). If an
therosclerosis imaging strategy using CAC scanning is
sed, the present data would suggest that repeat CAC
coring should not be performed for a minimum of 4 years
n individuals with a baseline score of CAC  0.
Proponents of CAC scoring for individuals with an
ntermediate Framingham risk score have primarily pro-
osed it as a one-time test for its ability to delineate the
tepwise increase in CHD events and death in individuals
ith increasing CAC score. Nevertheless, although the risk
or adverse clinical events associated with a single CAC
core may be approximately linear, the present data suggest
hat the rates of progression of CAC are not. In the present
tudy, the degree of baseline CAC score was the most
mportant determinant for rates of CAC progression. Thus,
one-time CAC score may be misleading. For example, an
ndividual who presents with a score of CAC  225 will
how incrementally higher rates of progression of CAC
han an individual with a score of CAC 75. Thus, the risk
ssociated with a score of CAC  225 as compared with a
core of CAC  75 may be higher not only because of the
igher absolute score but also because of the rate of
rogression to even higher CAC scores. If the utility of
AC screening is to be tested in clinical trials, it will be
mportant to define the natural history of progression to
etermine whether serial screening can enhance prediction
f incident risk of myocardial events, and if so, to determine
he appropriate screening interval.
In the present study, traditional CHD risk factors seemed
o be significantly associated with the overall conversion of
AC, but not robustly in its progression. These results do
ot argue against a CHD risk factor model. However, these
esults do suggest that once the diagnosis of CAD is made,
he degree of CAD becomes a critical and dominant
eterminant to coronary atherosclerosis progression, to a
reater degree than risk factors. Whether additional clinical
arkers of risk or other novel biomarkers of risk can
uccessfully predict CAD progression rates above and beyond
AC score is beyond the scope of this study, but should be
tudied. Indeed, the presence and absolute amount of CAC
eems to trump other risk factors for CAC progression.his finding is in accord with prior studies that have shown
he incremental ability of CAC score to prognosticate
dverse CHD events above and beyond traditional CHD
isk factors. In this regard, future studies evaluating the
ncremental predictive benefit of serial CAC scanning
gainst one-time CAC scanning may be useful to determine
hether a serial scanning strategy may more accurately
pdate CHD risk.
onclusions
he primary results of this study show a significant 4-year
warranty period” of a score of CAC  0. On development
f a score of CAC 0, baseline CAC score becomes the
ost robust predictor of CAC progression. Given the
agnitude of data supporting the use of CAC score to
dentify individuals at risk for CHD events, the results from
his study suggest that individuals with baseline score of
AC  0 do not require frequent repeat scanning and that
ater repeat CAC scanning of individuals with a score of
AC 0 may permit more accurate updating of CHD risk.
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